|By PR Newswire||
|April 19, 2013 08:00 AM EDT||
SEATTLE, April 19, 2013 /PRNewswire/ -- Presage Biosciences, a leader in precision oncology, today announced the initiation of a clinical trial and the first patient use of CIVO™, the company's precision oncology platform designed to improve treatment decisions for cancer patients. The single arm, non-therapeutic, observational study, being conducted at Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, is intended to evaluate the feasibility of Presage's CIVO in assessing lymphoma response to multiple microinjected candidate chemotherapy agents.
"Results from this initial study will assess the potential of CIVO to guide personalized clinical treatment for lymphoma patients," said Richard Klinghoffer, Ph.D., Vice President of Research & Development at Presage Biosciences. "CIVO is designed to enable analysis of the potential therapeutic effect of multiple drugs simultaneously following precise delivery of each agent to a distinct location on the patient's tumor. By employing this technology we hope to discern which drugs induce a localized anti-tumor response, indicative of therapeutic effect, prior to systemic administration of chemotherapy."
The trial will enroll up to 12 patients with either newly diagnosed lymphomas who have not yet received treatment or relapsed lymphoma previously treated with one or more agents in the R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Patients' lymphomas will be microinjected with up to four drugs comprising rituximab, vincristine, doxorubicin and prednisolone. Twenty-four hours later, the lymph node of interest will be removed and analyzed for target engagement and tissue response.
More information about this study, including additional eligibility criteria and contact information, can be found on clinicaltrials.gov. Study participants are not expected to benefit medically from participation or to directly benefit from the data generated in this feasibility study. None of the data will be released to the patient or treating physician in a manner that could be used to make treatment decisions. Patients may contact Jennifer Lindquist, Patient Care Coordinator / Lymphoma - Intake Office at Seattle Cancer Care Alliance, [email protected] or 206-288-6202 for more information.
"When a patient learns they have cancer, they want effective drugs that cause as little toxicity as possible. An expert panel from the American Society for Clinical Oncology found that previous attempts to predict cancer sensitivity to therapeutic agents using cancer cells grown in tissue culture dishes have not helped the way we hoped they would," said Oliver W. Press, M.D., Ph.D., a member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, Professor of Medicine at the University of Washington and the Principal Investigator for the study. "Oncologists and patients are eager for a reliable method to assess cancer drug sensitivity or resistance in the patient's own tumor. We look forward to evaluating the Presage's CIVO precision oncology platform and gathering patient data to evaluate the potential of this innovative approach."
About Presage CIVO™ Precision Oncology
Presage Biosciences' patented CIVO precision oncology platform offers an entirely novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient. The technology allows for the precise placement of multiple microdoses of candidate treatments through the skin and directly into a tumor. Such a controlled localization enables drug-specific responses to be measured for an array of drugs or drug combinations. These microdoses also provide the ability to analyze drug effects across the span of a living tumor thus capturing the heterogeneity of cancer cells.
About Presage Biosciences
Presage Biosciences is a leader in precision oncology. In addition to developing the CIVO™ precision oncology platform, the company is driving discovery of effective drug combinations. We are dedicated to improving cancer drug development so that patients can receive the most effective treatment possible. Presage partners with oncology-focused pharmaceutical companies through strategic alliances to provide previously inaccessible in vivo data to validate novel targets, promote drug candidates to the right indications, and discover effective drug combinations. Presage's CIVO is the world's only known technology to perform simultaneous comparisons of multiple drugs within a living tumor. Presage is privately held and based in Seattle. For more information, visit www.presagebio.com.
The project described was supported by Award Number R42CA144104 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
SOURCE Presage Biosciences
While DevOps promises a better and tighter integration among an organization’s development and operation teams and transforms an application life cycle into a continual deployment, Chef and Azure together provides a speedy, cost-effective and highly scalable vehicle for realizing the business values of this transformation. In his session at @DevOpsSummit at 19th Cloud Expo, Yung Chou, a Technology Evangelist at Microsoft, will present a unique opportunity to witness how Chef and Azure work tog...
Aug. 31, 2016 07:15 PM EDT Reads: 204
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, will discuss the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports. The session will include a working demo and a technical d...
Aug. 31, 2016 07:00 PM EDT Reads: 235
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Aug. 31, 2016 06:30 PM EDT Reads: 2,527
Between the mockups and specs produced by analysts, and resulting applications built by developers, there exists a gulf where projects fail, costs spiral, and applications disappoint. Methodologies like Agile attempt to address this with intensified communication, with partial success but many limitations. In his session at @DevOpsSummit at 19th Cloud Expo, Charles Kendrick, CTO at Isomorphic Software, will present a revolutionary model enabled by new technologies. Learn how business and deve...
Aug. 31, 2016 06:15 PM EDT Reads: 192
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Aug. 31, 2016 06:15 PM EDT Reads: 3,616
Although it has gained significant traction in the consumer space, IoT is still in the early stages of adoption in enterprises environments. However, many companies are working on initiatives like Industry 4.0 that includes IoT as one of the key disruptive technologies expected to reshape businesses of tomorrow. The key challenges will be availability, robustness and reliability of networks that connect devices in a business environment. Software Defined Wide Area Network (SD-WAN) is expected to...
Aug. 31, 2016 06:15 PM EDT Reads: 276
Developing software for the Internet of Things (IoT) comes with its own set of challenges. Security, privacy, and unified standards are a few key issues. In addition, each IoT product is comprised of (at least) three separate application components: the software embedded in the device, the back-end service, and the mobile application for the end user’s controls. Each component is developed by a different team, using different technologies and practices, and deployed to a different stack/target –...
Aug. 31, 2016 05:15 PM EDT Reads: 277
SYS-CON Events announced today that Hitrons Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Hitrons Solutions Inc. is distributor in the North American market for unique products and services of small and medium-size businesses, including cloud services and solutions, SEO marketing platforms, and mobile applications.
Aug. 31, 2016 05:00 PM EDT Reads: 876
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
Aug. 31, 2016 04:45 PM EDT Reads: 3,843
SYS-CON Events announced today that Numerex Corp, a leading provider of managed enterprise solutions enabling the Internet of Things (IoT), will exhibit at the 19th International Cloud Expo | @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Numerex Corp. (NASDAQ:NMRX) is a leading provider of managed enterprise solutions enabling the Internet of Things (IoT). The Company's solutions produce new revenue streams or create operating...
Aug. 31, 2016 04:39 PM EDT Reads: 245
Enterprises have forever faced challenges surrounding the sharing of their intellectual property. Emerging cloud adoption has made it more compelling for enterprises to digitize their content, making them available over a wide variety of devices across the Internet. In his session at 19th Cloud Expo, Santosh Ahuja, Director of Architecture at Impiger Technologies, will introduce various mechanisms provided by cloud service providers today to manage and share digital content in a secure manner....
Aug. 31, 2016 04:15 PM EDT Reads: 976
We are always online. We access our data, our finances, work, and various services on the Internet. But we live in a congested world of information in which the roads were built two decades ago. The quest for better, faster Internet routing has been around for a decade, but nobody solved this problem. We’ve seen band aid approaches like CDNs that attack a niche's slice of static content part of the Internet, but that’s it. It does not address the dynamic services-based Internet of today. It doe...
Aug. 31, 2016 04:12 PM EDT Reads: 258
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...
Aug. 31, 2016 04:00 PM EDT Reads: 1,135
As cloud adoption continues to transform business, today’s global enterprises are challenged with managing a growing amount of information living outside of the data center. The rapid adoption of IoT and increasingly mobile workforce are exacerbating the problem. Ensuring secure data sharing and efficient backup poses capacity and bandwidth considerations as well as policy and regulatory compliance issues.
Aug. 31, 2016 03:15 PM EDT Reads: 327
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Aug. 31, 2016 03:00 PM EDT Reads: 795